You are here
P&T February 2017
The National Evaluation System for Health Technology will be developed over the next five years to upgrade and improve the reporting of medical device adverse events. However, participants using the new system will incur significant capital costs.
The authors present the clinical outcomes and therapeutic application of newly approved pharmacotherapies for chronic lymphocytic leukemia and highlight emerging investigational therapeutic options.
In advance of the new guidelines being published this year, the author discusses treatment targets, diagnostics, and public policy with three hypertension experts.
A retrospective cohort study conducted in adult patients finds that intravenous acetaminophen use in certain ambulatory procedures is not associated with decreased PACU length of stay, but it may decrease postoperative pain.
We present several novel drugs in development for enhancing cognition, treating negative symptoms, and providing improved options for treatment-resistant patients. Drug makers aim to enhance safety profiles and increase patient compliance to therapy.
Key sessions on pharmacotherapy clinical trials across a wide span of disease states, including leukemia, graft-versus-host disease, myelofibrosis, multiple myeloma, and sickle cell disease, are reviewed.
The impact of disrespectful workplace behavior and how to address it
21st Century Cures bill may lead to faster drug/device approvals
Prasterone (Intrarosa) for the treatment of dyspareunia due to menopause; crisaborole (Eucrisa) for the topical treatment of atopic dermatitis; and tenofovir alafenamide (Vemlidy) for once-daily treatment of chronic hepatitis B virus infection
Brivaracetam (Briviact): a novel adjunctive therapy for partial-onset seizures